Author

C. McKnight

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Klumpp-Thomas· 3 shared M. Ceribelli· 3 shared C. J. Thomas· 2 shared E. Beck· 2 shared L. Chen· 2 shared Z. Itkin· 2 shared A. Bolomsky· 1 shared A. Kumari· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Klumpp-Thomas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia

E. J. Chory, M. Wang, M. Ceribelli, A. M. Michalowska, S. Golas, E. Beck, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, S. Divakaran, J. Bradner, J. Khan, B. E. Gryder, C. J. Thomas, B. Z. Stanton

This paper identifies synergistic drug combinations in AML using high-throughput methods and open-source tools, revealing synergies affecting histone H3 lysine-27 modification.

SLAS Discovery · Jun 1, 2023Peer-reviewedCancer Biology

Quantitative bioactivity signatures of dietary supplements and natural products

A. Yasgar, D. Bougie, C. McKnight, M. Miller, T. Peryea, M. Xia, P. Shah, X. Xu, P. Shinn, M. Itkin, C. Lynch, A. V. Zakharov, R. Eastman, J. Kouznetsova, D. Ngan, , A. Simeonov

The paper screens dietary supplements and natural products for bioactivity using in vitro assays and predicts their mechanisms of action by comparing activity profiles with approved drugs.

bioRxiv · Sep 14, 2022Pharmacology & Toxicology

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

Y. Yang, T. Oellerich, P. Chen, A. Bolomsky, M. Ceribelli, B. Haupl, G. W. Wright, J. D. Phelan, D. W. Huang, J. W. Lord, C. K. Van Winkle, X. Yu, J. Wisnieski, J. Q. Wang, F. A. Tosto, , R. M. Young

This study identifies how oncogenic RAS activates mTORC1 in multiple myeloma by co-opting amino acid sensing pathways through a novel signaling complex.

bioRxiv · Nov 28, 2021Cancer Biology

mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer

A. Kumari, L. Gesumaria, Y.-J. Liu, V. K. Hughitt, X. Zhang, M. Ceribelli, K. M. Wilson, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, C. Thomas, B. A. Mock, D. S. Schrump, H. Chen

This study identifies mTOR inhibition as a strategy to overcome RSK3-mediated resistance to BET inhibitors in small cell lung cancer, enhancing apoptosis and antitumor efficacy.

bioRxiv · Nov 8, 2021Cancer Biology